IKZF1 - Revision history

Jennelleh at 22:04, 18 March 2021

2021-03-18T22:04:13Z

← Older revision		Revision as of 17:04, 18 March 2021
Line 1:		Line 1:
	{{Under Construction}}		{{Under Construction}}

	See '''[https://ccga.io/index.php/Author_Instructions ''Author Instructions'']''' and '''[https://ccga.io/index.php/How_to_Curate_a_Gene_Page ''How to Curate a Gene Page]'''		See '''[https://ccga.io/index.php/Author_Instructions ''Author Instructions'']''' and '''[https://ccga.io/index.php/How_to_Curate_a_Gene_Page ''How to Curate a Gene Page'']'''

	==Primary Author(s)*==		==Primary Author(s)*==
Line 32:		Line 32:
	==Gene Overview==		==Gene Overview==

	Deletion of IKZF1 is a predictor of poor outcome and high risk of relapse in pediatric acute lymphoblastic leukemia.		Deletion of IKZF1 is a predictor of poor outcome and high risk of relapse in pediatric acute lymphoblastic leukemia.<ref>{{Cite journal\|last=Mullighan\|first=Charles G.\|last2=Su\|first2=Xiaoping\|last3=Zhang\|first3=Jinghui\|last4=Radtke\|first4=Ina\|last5=Phillips\|first5=Letha A.A.\|last6=Miller\|first6=Christopher B.\|last7=Ma\|first7=Jing\|last8=Liu\|first8=Wei\|last9=Cheng\|first9=Cheng\|date=2009-01-29\|title=Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia\|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2674612/\|journal=The New England journal of medicine\|volume=360\|issue=5\|pages=470–480\|doi=10.1056/NEJMoa0808253\|issn=0028-4793\|pmc=2674612\|pmid=19129520}}</ref>

	==Common Alteration Types==		==Common Alteration Types==
Line 100:		Line 100:
	'''[http://www.omim.org/entry/165215 ''MECOM'' by OMIM]''' - compendium of human genes and genetic phenotypes		'''[http://www.omim.org/entry/165215 ''MECOM'' by OMIM]''' - compendium of human genes and genetic phenotypes

	'''[https://databases.lovd.nl/shared/genes/MECOM ''MECOM'' by LOVD(3)]''' - Leiden Open Variation Database		'''[https://databases.lovd.nl/shared/genes/MECOM ''MECOM'' by LOVD(3)]''' - Leiden Open Variation Database

	'''[http://www.unav.es/genetica/TICdb/results.php?hgnc=MECOM ''MECOM'' by TICdb]''' - database of Translocation breakpoints In Cancer		'''[http://www.unav.es/genetica/TICdb/results.php?hgnc=MECOM ''MECOM'' by TICdb]''' - database of Translocation breakpoints In Cancer
Line 110:		Line 110:
	<references />		<references />
	===EXAMPLE Book===		===EXAMPLE Book===

	#Arber DA, et al., (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p129-171.		#Arber DA, et al., (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p129-171.

	=== EXAMPLE Internet Resource ===		===EXAMPLE Internet Resource===
	# author name(s). Date (if possible). page title, website title, web address, and date accessed.
	# Cingam, S. R. and Koshy, N.V. (2017). Cancer, Leukemia, Promyelocytic, Acute (APL, APML). https://www.ncbi.nlm.nih.gov/books/NBK459352/ Accessed August 3, 2018.		#author name(s). Date (if possible). page title, website title, web address, and date accessed.
			#Cingam, S. R. and Koshy, N.V. (2017). Cancer, Leukemia, Promyelocytic, Acute (APL, APML). https://www.ncbi.nlm.nih.gov/books/NBK459352/ Accessed August 3, 2018.

	== Notes ==		==Notes==
	<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.		<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.

Jennelleh at 22:02, 18 March 2021

2021-03-18T22:02:21Z

@@ Line 1: / Line 1: @@
-== Contributors ==
+{{Under Construction}}
-== Prevalence ==
+See '''[https://ccga.io/index.php/Author_Instructions ''Author Instructions'']''' and '''[https://ccga.io/index.php/How_to_Curate_a_Gene_Page ''How to Curate a Gene Page]'''
-== Genes Involved ==
+==Primary Author(s)*==
-==Diagnostic Testing==
+__TOC__
-== Clinical Significance ==
+==Genomic Location==
-== Therapeutics ==
+Put your text here
-== Links ==
+==Cancer Category/Type==
-== References ==
+==Gene Overview==
-Mullighan, Charles G., et al. "Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia." New England Journal of Medicine 360.5 (2009): 470-480.

Linda.Baughn: Created page with "== Contributors == Linda B. Baughn, PhD == Description == Deletion of IKZF1 is a predictor of poor outcome and high risk of relapse in pediatric acute lymphoblastic leukemia =..."

2017-02-22T12:07:49Z

Created page with "== Contributors == Linda B. Baughn, PhD == Description == Deletion of IKZF1 is a predictor of poor outcome and high risk of relapse in pediatric acute lymphoblastic leukemia =..."

New page

== Contributors ==
Linda B. Baughn, PhD
== Description ==
Deletion of IKZF1 is a predictor of poor outcome and high risk of relapse in pediatric acute lymphoblastic leukemia
== Tumor Types ==

== Prevalence ==

== Genes Involved ==

==Diagnostic Testing==

== Clinical Significance ==

== Therapeutics ==

== Links ==

== References ==
Mullighan, Charles G., et al. "Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia." New England Journal of Medicine 360.5 (2009): 470-480.